… ), a record of use of the factor Xa inhibitors rivaroxaban or apixaban, andexanetáalfa or 4F-PCC
… with other bleed types, lack of reporting on the time since the last dose of FXa inhibitor or …

… bleeding associated with the use of rivaroxaban or apixaban. Controversy exists over the …
To our knowledge, this is the largest reported single center observational study of real-world …

… studies that directly compared treatment with rivaroxaban and apixaban in adult patients with
acute VTE and reported both … published study comparing PK properties and anti-factor Xa …

… factor Xa inhibitors (edoxaban, rivaroxaban, and apixaban) … Although several observational
studies have compared the … We used ICD‐10 codes recorded in either DPC claims or FFS …

… also reported a decreased risk for major bleeding with apixaban… Our observational study had
several limitations. First, we … peak anti–factor Xa levels in patients receiving apixaban might …

… previously reported in the Korean population (36). … In addition, as with all observational
studies, we cannot rule out the … antidote to oral factor Xa inhibitors (rivaroxaban, apixaban, and …

… This retrospective, observational cohort study was approved by … All anti-Xa levels for
apixaban and rivaroxaban ordered at … Lastly, the reported upper limit of our institution's anti-Xa …

… that standard doses of apixaban or rivaroxaban, along with … apixaban exposure. Although
the chromogenic assay used to support apixaban clinical development reported anti-factor Xa …

… In May 2018, the US Food and Drug Administration approved andexanet alfa for the
reversal of anticoagulation with apixaban and rivaroxaban in life-threatening or uncontrolled …

… apixaban, edoxaban, or rivaroxaban) or enoxaparin (only in active cancer patients) constituted
the start of the observational … pg inhibitors, which may interact with DOACs, were recorded…